We hope the first full week back treated you well. The market got a bit choppy last week—we address this in an extended version of our regular Monday Hillside Ugly 20 recap.
We also provide, in response to reader requests, more of an explanation of the similarities and differences between our two proprietary measures to date, HARP (Hillside Adjusted Risk Points) and HOCS (Hillside Overall Convertible Score). We are now providing HOCS data with each name we discuss at length in Hybrid Vigor. Eventually we intend to provide more comprehensive HOCS listings.
In this issue we feature Kent Bailey’s update on BioMarin, including some perhaps overlooked reasons to focus on the name right now. We also feature Jeff Alton’s comments on UTi Worldwide—Jeff explains why it’s not too late to get in despite a recent pop.
We hope to see many of you at our cocktail event this Thursday. We’re expecting an excellent turnout, but if you’d like to attend and haven’t received an invitation, it’s not too late to let us know.